Drugs / rMenB+OMV NZ vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03493919 | Mar 2018 → May 2022 | meningococcal meningitis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rMenB+OMV NZ vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03493919 ↗ |
| Modality | Vaccine | “Two doses of rMenB+OMV NZ vaccine were administered intramuscularly at Day 1 and Day 61.” NCT03493919 ↗ |
| Route | Intramuscular | “Two doses of rMenB+OMV NZ vaccine were administered intramuscularly at Day 1 and Day 61.” NCT03493919 ↗ |